0001209191-20-051235.txt : 20200918
0001209191-20-051235.hdr.sgml : 20200918
20200918210012
ACCESSION NUMBER: 0001209191-20-051235
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200916
FILED AS OF DATE: 20200918
DATE AS OF CHANGE: 20200918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROBINS CHAD M
CENTRAL INDEX KEY: 0001780649
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 201185085
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-16
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780649
ROBINS CHAD M
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1551 EASTLAKE AVE E STE 200
SEATTLE
WA
98102
1
1
0
0
CEO and Chairman
Common Stock
2020-09-16
4
M
0
16680
0.33
A
1794860
D
Common Stock
2020-09-16
4
S
0
6180
45.47
D
1788680
D
Common Stock
2020-09-16
4
S
0
5000
46.45
D
1738680
D
Common Stock
2020-09-16
4
S
0
5100
47.46
D
1778580
D
Common Stock
2020-09-16
4
S
0
400
48.26
D
1778180
D
Common Stock
2020-09-17
4
M
0
16680
0.33
A
1794860
D
Common Stock
2020-09-17
4
S
0
2600
44.48
D
1792260
D
Common Stock
2020-09-17
4
S
0
14080
45.26
D
1778180
D
Common Stock
2020-09-18
4
M
0
16680
0.33
A
1794860
D
Common Stock
2020-09-18
4
S
0
8100
45.28
D
1786760
D
Common Stock
2020-09-18
4
S
0
8580
46.13
D
1778180
D
Stock Option (Right to Buy)
0.33
2020-09-16
4
M
0
16680
0.00
D
2021-12-20
Common Stock
16680
228000
D
Stock Option (Right to Buy)
0.33
2020-09-17
4
M
0
16680
0.00
D
2021-12-20
Common Stock
16680
211320
D
Stock Option (Right to Buy)
0.33
2020-09-18
4
M
0
16680
0.00
D
2021-12-20
Common Stock
16680
194640
D
These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.08 to 46.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.11 to 47.07, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.18 to 48.14, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.26 to 48.27, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.35 to 44.57, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.58 to 45.57, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.79 to 45.74, inclusive.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.80 to 46.55, inclusive.
The options are fully vested and exercisable.
/s/ Chad M. Robins by Eric Billings, Attorney-in-Fact
2020-09-18